InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy

Atrial fibrillation and normal or abnormal heart rate rythm as a cardiac disorder as a human organ with healthy and unhealthy ecg monitoring in a 3D illustration style.
InCarda ultimately hopes to offer a major change in atrial fibrillation therapy

More from Financing

More from Business